Document ID: FDA-2014-N-0002-0018
Agency: fda
Document Type: Rule
Title: Zoetis Inc., et al.; Withdrawal of Approval of New Animal Drug
Applications for Combination Drug Medicated Feeds Containing an
Arsenical Drug; Correction
Posted Date: 2014-04-07T04:00Z

[Federal Register Volume 79, Number 66 (Monday, April 7, 2014)]
[Rules and Regulations]
[Page 18990]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-07702]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 556 and 558

[Docket No. FDA-2014-N-0002]

Zoetis Inc., et al.; Withdrawal of Approval of New Animal Drug 
Applications for Combination Drug Medicated Feeds Containing an 
Arsenical Drug; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notification of withdrawal of approval; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) published a document in 
the Federal Register of February 27, 2014, concerning the voluntary 
withdrawal of approval of new animal drug applications (NADAs). The 
document contained an incorrect list of NADAs.

DATES: This correction is effective April 7, 2014.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for 
Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 
Standish Pl., Rockville, MD 20855, 240-276-9019, 
George.haibel@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In FR Doc. 2014-02616, appearing on page 
10974 in the Federal Register of February 27, 2014, the following 
corrections are made:
    On page 10974, in the third column, in the 2d line of the 
``SUMMARY'' section remove ``69'' and add in its place ``68''.
    On page 10975, the first bulleted text ``Huvepharma AD, 5th Floor, 
3A Nikolay Haitov Str., 1113 Sofia, Bulgaria has requested that FDA 
withdraw approval of the following 16 NADAs and 8 ANADAs'' is corrected 
to read ``Huvepharma AD, 5th Floor, 3A Nikolay Haitov Str., 1113 Sofia, 
Bulgaria, has requested that FDA withdraw approval of the following 15 
NADAs and 8 ANADAs''; and on the same page in the table, the entry 
``013-461 3-NITRO (roxarsone)/AMPROL Plus (amprolium and ethopabate).'' 
is removed.

    Dated: April 2, 2014.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2014-07702 Filed 4-4-14; 8:45 am]
BILLING CODE 4160-01-P